Could a Pill Add Years to Your Dog's Life? Scientists Are Finding Out.

Doges Editorial · 2026-06-07 · 5 min read

Could a Pill Add Years to Your Dog's Life? Scientists Are Finding Out.

DOGES

Two major clinical trials — one testing rapamycin, one testing a new drug called LOY-002 — are trying to answer whether aging in dogs can be pharmacologically slowed. One drug already has FDA conditional approval.

The dog sleeping at your feet — the one with the graying muzzle and the stiff mornings, the one who takes longer to stand up than she used to — is at the center of a question scientists have been working on for years. Can the biology of aging be slowed? And if so, would a pill do it?

The answer is not yet. But it is closer than it has ever been. Two clinical trials are currently running, enrolling thousands of dogs, testing whether drugs already understood in other contexts can extend healthy years in a species that ages faster than we do and, for most of us, far too soon.

Two Trials, One Question

The first trial is built around rapamycin, an immunosuppressant already used in human medicine that has shown striking effects on lifespan in mice. The TRIAD study, run by the Dog Aging Project, is testing whether those effects translate to dogs — whether the same cellular mechanism that slows aging in rodents operates similarly in a species much closer to humans in physiology and environmental exposure.

Rapamycin works by dampening a cellular pathway called mTOR — mechanistic target of rapamycin — which governs how cells respond to nutrients and stress. When mTOR activity is modulated, cells appear to age more slowly. The mechanism is well-characterized; what the TRIAD trial is measuring is whether the effect is meaningful in dogs, at safe doses, over a realistic treatment period.

The second trial involves LOY-002, a drug developed by Loyal, a San Francisco biotech company dedicated entirely to the problem of dog aging. The STAY study is larger: roughly 1,300 enrolled dogs, a four-year double-blind design, measuring not just survival but healthspan — the period of life in which a dog remains active, cognitively sharp, and physically capable.

Loyal's Two-Drug Strategy

Loyal is actually pursuing two separate drugs targeting two different mechanisms. LOY-001 is an injectable designed specifically for large and giant breeds — Great Danes, Saint Bernards, Mastiffs, the dogs whose shorter lifespans have long puzzled researchers. The working theory: large breeds have elevated levels of IGF-1, a growth hormone that may accelerate aging in dogs the way size accelerates it. LOY-001 aims to reduce IGF-1 levels in large dogs, pulling their aging trajectory closer to that of smaller breeds who live, on average, several years longer.

LOY-002 takes a different angle. Rather than targeting growth hormone in a specific size class, it works on metabolism in senior dogs broadly — all sizes, administered orally. The hypothesis is that altering metabolic rate in older dogs will extend the period of healthy function, in the same way that caloric restriction has been shown to extend healthy lifespan in a range of species.

LOY-001 has already received conditional approval from the FDA — a regulatory pathway that allows a drug to reach market before all efficacy data is finalized, provided safety is established and there is reasonable expectation of effectiveness. That the FDA applied this pathway to a longevity drug for dogs is itself significant. It marks the first time the agency has formally recognized slowing aging as a treatable condition, at least in a non-human species.

The Consent Problem

Jane Sykes, a veterinary internal medicine specialist who wrote about these trials in The Washington Post, raised a question that tends to get lost in the excitement around longevity research: dogs can't consent.

That's not a disqualifying concern. But it changes the frame. Every long-term drug intervention in a dog is a decision made by a human on behalf of the dog, using values and priorities the dog can't communicate. Which means the question isn't simply 'does it extend life?' — it's 'extend which kind of life, at what quality, measured by whose standards?'

A dog who lives two additional years but spends those years with reduced appetite, interrupted sleep, or chronic low-level discomfort hasn't been given a gift. The STAY trial is designed with this in mind — healthspan, not just lifespan, is the primary outcome measure. But the distinction between a life that is longer and a life that is better remains genuinely difficult to measure in a being who can't tell you which it is.

The trials are also running against a backdrop of owner hope that can distort what evidence is expected to deliver. Clinical trials in dogs, like those in humans, produce probabilistic results — a drug that works for seventy percent of enrolled animals does not work for the thirty. The dogs for whom it works tend to make the news; the ones for whom it doesn't tend not to.

What Actually Works Right Now

The best evidence we currently have for extending healthy years in dogs points to three things: appropriate diet, maintaining a healthy weight, and regular exercise. These aren't glamorous, but they are proven.

— Jane Sykes, veterinary internal medicine specialist, The Washington Post

The mundane advice lands differently when you've just read about a four-year double-blind pharmaceutical trial. But the three things Sykes names have evidence behind them that the trials are still working to match. Overweight dogs live measurably shorter lives. Muscle mass matters in aging — dogs who maintain strength age more slowly, at least functionally. And regular movement, the sustained and varied kind, appears to affect how dogs age in ways that are still being characterized.

That last point is worth dwelling on. Not all exercise is equivalent. The evidence suggests that walks with variety — different terrain, different smells, the cognitive engagement of an unfamiliar route — do something that the same ten-minute loop around the block doesn't. Sniff-heavy walking, in particular, has attracted attention from researchers studying canine cognitive aging. The nose leads the brain leads the body; a dog who is actively investigating the world is a dog whose brain is working.

The Longer Arc

The STAY trial won't complete until 2028 at the earliest. The TRIAD rapamycin results are still pending full analysis. What we have right now is a plausible mechanism in two drugs, early safety signals that are encouraging, and two large well-designed trials that will tell us, eventually, whether 'plausible' becomes 'proven.'

In the meantime, the graying muzzle is there on your couch. The stiff mornings are real. The thing the trials are ultimately trying to preserve — the years when a dog is curious, mobile, present, recognizably herself — is happening right now, this morning, before the leash is even clipped.

The pill may come. The walk is already here.